Antipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in Schizophrenia

Antipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in Schizophrenia

Author Levin, Raquel Autor UNIFESP Google Scholar
Almeida, Valeria Autor UNIFESP Google Scholar
Peres, Fernanda Fiel Autor UNIFESP Google Scholar
Calzavara, Mariana Bendlin Autor UNIFESP Google Scholar
Silva, Neide Derci da Autor UNIFESP Google Scholar
Suiama, Mayra Akimi Autor UNIFESP Google Scholar
Niigaki, Suzy Tamie Autor UNIFESP Google Scholar
Zuardi, Antonio Waldo Autor UNIFESP Google Scholar
Hallak, Jaime Eduardo Cecilio Google Scholar
Crippa, Jose Alexandre de Souza Google Scholar
Abilio, Vanessa Costhek Autor UNIFESP Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
CNPq
Abstract Objectives: Clinical and neurobiological findings suggest that cannabinoids and their receptors are implicated in schizophrenia. Cannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa plant, has been reported to have central therapeutic actions, such as antipsychotic and anxiolytic effects. We have recently reported that spontaneously hypertensive rats (SHR) present a deficit in contextual fear conditioning (CFC) that is specifically ameliorated by antipsychotics and aggravated by proschizophrenia manipulations. These results led us to suggest that the CFC deficit presented by SHR could be used as a model to study emotional processing impairment in schizophrenia. The aim of this study is to evaluate the effects of CBD and rimonabant (CB1 receptor antagonist) on the contextual fear conditioning in SHR and Wistar rats (WR). Methods: Rats were submitted to CFC task after treatment with different doses of CBD (experiment 1) and rimonabant (experiment 2). Results: In experiment 1, SHR showed a decreased freezing response when compared to WR that was attenuated by 1 mg/kg CBD. Moreover, all CBD-treated WR presented a decreased freezing response when compared to control rats. In experiment 2, SHR showed a decreased freezing response when compared to WR that was attenuated by 3 mg/kg rimonabant. Discussion: Our results suggest a potential therapeutical effect of CBD and rimonabant to treat the emotional processing impairment presented in schizophrenia. In addition, our results reinforce the anxiolytic profile of CBD.
Keywords Schizophrenia
cannabidiol
rimonabant
contextual fear conditioning
SHR
Language English
Sponsor Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Grant number FAPESP: 2010/07994- 3
Date 2012-11-01
Published in Current Pharmaceutical Design. Sharjah: Bentham Science Publ Ltd, v. 18, n. 32, p. 4960-4965, 2012.
ISSN 1381-6128 (Sherpa/Romeo, impact factor)
Publisher Bentham Science Publ Ltd
Extent 4960-4965
Origin http://dx.doi.org/10.2174/138161212802884735
Access rights Closed access
Type Review
Web of Science ID WOS:000309512900009
URI http://repositorio.unifesp.br/11600/43467

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account